Clinical trials

-
RAN proteins in Ataxia -
Stimulation-induced ataxia in essential tremor - Investigator
- Adolfo Ramirez-Zamora
-
Respiratory training in Friedreich's ataxia - Investigator
- Carmen Leon Astudillo
-
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known as鈥�
- Investigators
- Matthew R Burns, Sub Subramony
- Ages
- 6 Years - N/A
- Sexes
- All
-
JIVE (LARIMAR) To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration of CTI-1601 over 28 days in subjects with Friedreich's ataxia (FRDA).
- Investigator
- Sub Subramony
- Ages
- 18 Years - N/A
- Sexes
- All
-
Frataxin The purpose of this research study is to determine a way to measure frataxin messenger RNA (mRNA) in fluids such as blood and cerebrospinal fluid (CSF) from patients with Friedreich's ataxia (FRDA). The gene mutation in FRDA leads to low levels of鈥�
- Investigator
- Sub Subramony
- Ages
- 18 Years - 65 Years
- Sexes
- All
-
TRACK-FA This is a natural history study prospectively investigating neuroimaging markers of disease progression in children and adults with Friedreich ataxia (FA). There will be three assessment periods (baseline, 12 and 24 months). The study will include鈥�
- Ages
- 5 Years - N/A
- Sexes
- All
-
Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
- Investigator
- Ali Ataya
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
IMPALA-2 160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive鈥�
- Investigator
- Ali Ataya
- Ages
- 18 Years - N/A
- Sexes
- All
-
Sapphire This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
- Investigator
- Ali Ataya
- Ages
- 18 Years - 99 Years
- Sexes
- All